Do you have "refractory", treatment-resistant rheumatoid arthritis (RA)?

If so, you may be eligible for a study for a new therapy to help people like you. Participation in this study will not come at an additional cost to you.


This study, called the Frontier Study, is supported by Amgen.

Visit the Study Website

Or learn a little more about this study below.

What is the purpose of the Frontier Study?

This study aims to assess the effectiveness of a study drug and how it impacts RA symptoms, particularly in people with RA who have not responded well to other treatments.


Do I qualify to participate in this study?

You may be eligible to participate in this study if you:



  • Are between the ages of 18 - 75 years old
  • Have a confirmed diagnosis of rheumatoid arthritis
  • Have been told by your doctor that your rheumatoid arthritis is refractory*


*‘Refractory’ means your rheumatoid arthritis does not respond to standard treatment options or improve despite trying different medications.


You may not be eligible for this study if you:



  • Have other current inflammatory joint disease other than RA
  • Have had any type of organ transplant


Other eligibility criteria apply and will be evaluated by a study doctor if you choose to continue with screening for the study.

Where are the clinical sites?

    • Columbia University Medical Center
    • MetroHealth Medical Center
    • Northwell Health
    • University of California Irvine
    • University of Colorado
    • University of California Los Angeles
    • University of Rochester Medical Center
    • Emory University
    • Johns Hopkins University
    • Mayo Clinic
    • University of Pittsburgh Medical Center
    • Massachusetts General Hospital
    • Seattle Rheumatology
    • Cleveland Clinic Foundation
    • University Medical Center New Orleans
    • Augusta University
    • University of Arizona, Arizona Arthritis Center
    • Northwell Health
    • Boston University School of Medicine
    • New York Medical College

  • Australia

    • Hospital St. Vincent's de Sídney
    • Linear Clinical Research Limited
    • Hospital Royal Prince Alfred
    • Hospital Fiona Stanley
    • Centre Hospitalier Universitaire de Liege - Sart Tilman
    • Cliniques Universitaire Saint Luc Université Catholique de Louvain
    • Universitaire Ziekenhuis Gent
    • Universitaire Ziekenhuis Leuven - Campus Gasthuisberg
    • William Osler / Brampton Civic
    • Hospital Europeen Georges Pompidou
    • Centre Hospitalier Universitaire de Lyon - Hôpital Edouard Herriot
    • Hôpital de la Conception
    • Hôpital Bichat Claude Bernard
    • Centre Hospitalier Universitaire de Strasbourg - Nouvel Hôpital Civil
    • Centre Hospitalier Universitaire de Toulouse - Hôpital Rangueil
    • Centre Hospitalier Regional Universitaire de Lille - Hôpital Claude Huriez
    • Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre
    • Centre Hospitalier Universitaire de Strasbourg - Hôpital de Hautepierre
    • Centre Hospitalier Universitaire de Toulouse - Hôpital Purpan
    • Hôpital Cochin
    • Klinikum der LMU Muenchen
    • Universitaetsklinikum Leipzig
    • Universitaetsklinikum Duesseldorf AoeR
    • Krankenhaus Porz am Rhein gGmbH
    • Johannes Wesling Klinikum Minden
    • IRCCS Ospedale San Raffaele
    • IRCCS Istituto Clinico Humanitas
    • Ospedale San Giovanni Bosco
    • Azienda Universitaria Ospedaliera Consorziale Policlinico Bari
    • Unidade Local de Saude de Lisboa Ocidental, EPE - Hospital Santa Cruz
    • Unidade Local de Saude de Gaia-Espinho, EPE

  • España

    • Hospital Universitario 12 de Octubre
    • Hospital Clinic i Provincial de Barcelona
    • Hospital Universitari Vall d Hebron
    • Hospital Universitario Marques de Valdecilla
    • Addenbrookes Hospital
    • Leicester General Hospital
    • Freeman Hospital
    • Western General Hospital
    • Musgrave Park Hospital
    • Guys Hospital

What should I expect?

1. Submit Online Questionnaire 

Este cuestionario le pedirá su información de contacto y algunas preguntas sobre su historial médico para determinar si cumple con los requisitos. Luego, seleccione un horario para una breve llamada telefónica con PatientWing. Enviar el cuestionario es voluntario y no implica ningún compromiso para participar en el estudio.

2. Speak With PatientWing

PatientWing is helping to identify potential individuals who may be interested in the Frontier Study.
You will have a short call with PatientWing to answer additional questions about your medical history and PatientWing will help collect your medical records.

3. Hable con un representante del centro de investigación.

After your conversation with PatientWing, you will meet the research team who will review your medical records. If the research team thinks you are eligible, they will schedule a screening visit. The research team will provide more information during your conversations with them. No question is a bad question, so please share your concerns with the team!

4. Study Participation

After you've completed the screening period, the research team will notify you about your eligibility. If you are enrolled in the study, you should expect the following:

  • You will visit the study site approximately 20 times over 12 months.
  • You will have follow-up visits with the study team to investigate your response to the study drug.

Frequently Asked Questions (FAQ) about this study

  • Complete el cuestionario y proporcione información básica para expresar su interés en participar en el estudio. También puede enviar un correo electrónico a studies@patientwing.com o llamar/enviar un mensaje de texto al 213-459-2979.

  • ¿Cómo participa PatientWing en este proceso de estudio clínico?

    We partner with study sponsors to match individuals with clinical studies. Our dedicated team provides clear information about available studies, connects you with research sites, and ensures you have the resources and guidance you need at every step. We are here to support your journey with clinical research!

  • The study drug will be given as subcutaneous injection once a week.

  • Expenses such as travel and parking are reimbursed within reasonable limits.

  • ¿Con qué frecuencia debo visitar el sitio de investigación?

    You will have 20 visits to the research site during the study period.

  • Your participation may be about 13 months.

  • No, this study does not have a placebo. You will receive the study drug, blinatumomab, if you participate in the study.

  • ¡SÍ! AiArthritis ha creado una herramienta que puede ayudarle a usted, a sus seres queridos y a su médico a decidir si un ensayo clínico es adecuado para usted.


    You can download this on our main clinical trials page,  as well as more guidance about clinical trial participate generally.

This study is affiliated with Amgen.